Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 15/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | ADK | P55263 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17199267 | 0.85 | GRM5 (0.50) | GRM5KCNH2ABL1SLC6A2ADK | |
| SCHEMBL3881087 | 0.82 | GRM5 (0.70) | GRM5KCNH2ABL1SLC6A2 | |
| Hydrochloric Acid SCHEMBL3881392 | 0.81 | GRM5 (0.68) | GRM5KCNH2ABL1SLC6A2 | |
| SCHEMBL4562631 | 0.73 | KCNH2 (0.67) | GRM5KCNH2CYP2D6 | |
| SCHEMBL30707869 | 0.73 | KCNH2 (0.67) | GRM5KCNH2CYP2D6 | |
| SCHEMBL15021802 | 0.73 | GRM5 (0.42) | GRM5KCNH2 | |
| SCHEMBL15750940 | 0.71 | GRM5 (0.37) | GRM5CYP2D6 | |
| SCHEMBL15750733 | 0.71 | GRM5 (0.41) | GRM5 | |
| Charcoal, Activated SCHEMBL31286308 | 0.71 | KCNH2 (0.64) | GRM5KCNH2CYP2D6 | |
| SCHEMBL3873127 | 0.70 | GRM5 (0.71) | GRM5KCNH2ABL1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150045551-A1 | FUSED AZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-02-12 | — | — | US | disclosed |
| US-20150045551-A1 | FUSED AZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-02-12 | — | — | US | disclosed |
| US-20150045551-A1 | FUSED AZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-02-12 | — | — | US | disclosed |
| EP-2832722-A1 | FUSED AZOLE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2015-02-04 | — | — | EP | disclosed |
| EP-2832722-A1 | FUSED AZOLE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2015-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045551-A1 | FUSED AZOLE DERIVATIVE | AVPR1B, AVPR1A, GRIN2B | GRM5 144/4885KCNH2 3136/4885ABL1 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.